Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Lena Lemke
Observed names:
L. Lemke,
Lemke, Lena
Observed institution:
Hexal (Germany)
ORCID:
0009-0006-5375-9717
Observed ORCID:
0009-0006-5375-9717
OpenAlex ID:
A5045529581
GP2017, an adalimumab biosimilar: pharmacokinetic similarity to its reference medicine and pharmacokinetics comparison of different administration methods
2019
·
Oliver von Richter
, Lena Lemke
, et al.
·
Expert Opinion on Biological Therapy
·
34
Treatment with SDZ-ADL, an Adalimumab Biosimilar, in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis: Results of Patient-Reported Outcome Measures from Two Phase III Studies (ADMYRA and ADACCESS)
2021
·
Andrew Blauvelt
, Craig L. Leonardi
, et al.
·
BioDrugs
·
21
PDF
Signal-to-noise Ratio to Assess Magnitude, Kinetics and Impact on Pharmacokinetics of the Immune Response to an Adalimumab Biosimilar
2023
·
Davide Guerrieri
, Matej Horvat
, et al.
·
Bioanalysis
·
18
‘Totality of Evidence’ Approach in the Development of GP2017, an Approved Adalimumab Biosimilar
2024
·
Norman Gaylis
, Charlotte Both
, et al.
·
Advances in Therapy
·
9
PDF
Differences in immunogenicity associated with non-product related variability: insights from two pharmacokinetic studies using GP2017, an adalimumab biosimilar
2019
·
Oliver von Richter
, Lena Lemke
, et al.
·
Expert Opinion on Biological Therapy
·
9
GP2017-HCF, a high concentration formulation, demonstrates similar pharmacokinetics, immunogenicity and safety to GP2017, an approved adalimumab biosimilar
2022
·
Oliver von Richter
, Terry O’Reilly
, et al.
·
Expert Opinion on Biological Therapy
·
7
Comparing anti-drug antibody signal-to-noise ratios to assess immunogenicity and interchangeability in adalimumab biosimilar studies
2024
·
Lena Lemke
, Andrew Blauvelt
, et al.
·
Expert Opinion on Biological Therapy
·
3
PDF
Ab0208 Do Low Concentrations of Citrate in an Adalimumab Formulation Impact the Incidence And/or Intensity of Injection Site Pain? Data From Phase I and Iii Studies Assessing the Local Tolerance of Gp2017 (adalimumab Biosimilar, Sdz-adl) in Healthy Volunteers, Rheumatoid Arthritis, and Psoriasis Patients
2021
·
P. Wiland
, A. Blauvelt
, et al.
·
Annals of the Rheumatic Diseases
·
1
Neoadjuvant nivolumab with or without visugromab in muscle-invasive bladder cancer: the phase 2a GDFATHER-NEO trial
2026
·
Andrea Necchi
, Chiara Mercinelli
, et al.
·
Nature Medicine
PDF
Correction to: Efficacy, Safety, and Immunogenicity of SDZ-ADL, an Adalimumab Biosimilar, in Biologic-Naïve and Switched Patients with Immune-Mediated Inflammatory Diseases: A Literature Review
2025
·
Piotr Wiland
, Charlotte Both
, et al.
·
Advances in Therapy
PDF
Efficacy, Safety, and Immunogenicity of SDZ-ADL, an Adalimumab Biosimilar, in Biologic-Naïve and Switched Patients with Immune-Mediated Inflammatory Diseases: A Literature Review
2025
·
Piotr Wiland
, Charlotte Both
, et al.
·
Advances in Therapy
PDF
A Plain Language Summary Describing how Two Different Concentrations of GP2017, a Biosimilar Adalimumab Medicine, are Associated with Similar Drug Levels within the Body
2023
·
Silvio Danese
, Piotr Wiland
, et al.
·
Immunotherapy
PDF
S1057 A Randomized Phase I Study Comparing Pharmacokinetics, Safety and Immunogenicity of High Concentration Formulation (100 mg/mL) With GP2017 Formulation (50 mg/mL), an Adalimumab Biosimilar, in Healthy Male Subjects
2022
·
Juan Carlos Rondon
, Oliver Von Richter
, et al.
·
The American Journal of Gastroenterology
GP2017, an adalimumab biosimilar: pharmacokinetic similarity to its reference medicine and pharmacokinetics comparison of different administration methods
2019
·
von Richter, Oliver
, Lemke, Lena
, et al.
·
Figshare
Show more works
View as search
Works count:
18
Citation count:
102
H-index:
6
I10-index:
3
Year
Topic
Type
